Clinical Research Protocols for the Elderly and for Myelodysplastic Syndromes

Cancer Control. 2000;7(6) 

Introduction

  • EORTC-06993-AML-15 Phase II Pilot Study of Gemtuzumab Ozogamicin With or Without Mitoxantrone, Etoposide, Cytarabine, and Idarubicin in Elderly Patients With Acute Myeloid Leukemia

    Chairperson: Sergio Amadori. Telephone: 39-06-5914745. Lead organization: EORTC Lung Cancer Group. Age range: 61 and over.

  • EORTC-06954 Phase III Randomized Study of Acute Myeloid Leukemia in Elderly Patients (AML-13): MICE (DHAD/ARA-C/VP-16) With vs Without G-CSF Followed by Oral vs Intravenous Mini-ICE (IDA/ARA-C/VP-16) Followed in Selected Patients by BAVC (BCNU/ AMSA/VP-16/ARA-C) With PBSC Support Chairperson: Theo De Witte. Telephone: 024-361-47-62. Lead organization: EORTC Leukemia Group. Age range: 61 to 80.

  • CWRU-3399, NCI-G00-1853 Phase II Study of Stereotactic Radiosurgery in Elderly Patients or Patients With Poor Performance Status Who Have Brain Metastases

    Chairperson: Huong Pharm. Telephone: 216-844-2515. Lead organization: Ireland Cancer Center. Age range: Over 18.

  • NCCTG-967351 Phase II Study of Radiation Therapy and High Dose Corticosteroids for Elderly Patients With Primary Central Nervous System Non-Hodgkin's Lymphoma

    Chairperson: Brian Patrick O'Neill. Telephone: 507-284-8431. Lead organization: North Central Cancer Treatment Group. Age range: 70 and over.

  • SWS-SAKK-25/99, EU-99007 Phase I/II Study of Capecitabine and Vinorelbine in Elderly Women With Metastatic Breast Cancer With or Without Bone Involvement

    Chairperson: D. Hess. Telephone: 071-494-11-11. Lead organization: Swiss Institute for Applied Cancer Research. Age range: 65 and over.

  • IBCSG-10-93, NCI-F93-0008, EU-93013 Phase III Randomized Study of Surgery With or Without Axillary Node Clearance Followed by Adjuvant Tamoxifen in Elderly Women With Breast Cancer

    Chairperson: Diana Crivellari. Telephone: 39-434-659206. Lead organization: International Breast Cancer Study Group. Age range: 60 and over.

  • E-1299 Phase II Study of Fluorouracil-Uracil and Leucovorin Calcium in Elderly Patients With Metastatic Colorectal Cancer

    Chairperson: Howard Hochster. Telephone: 212-263-6485. Lead organization: Eastern Cooperative Oncology Group. Age range: 75 and over.

  • CWRU-4496, NCI-G97-1350, AMC-1C-93 Phase II Study of Oral Combination Chemotherapy and Granulocyte Colony-Stimulating Factor in Elderly Patients With Intermediate and High Grade Non-Hodgkin's Lymphoma)

    Chairperson: Scot C. Remick. Telephone: 216-844-1196. Lead organization: Ireland Cancer Center. Age range: 60 and over.

  • CRC-TU-NH3003, EU-93028 Phase III Randomized Study of CHOP (CTX/DOX/VCR/PRDL) vs MCOP (DHAD/CTX/VCR/PRDL) in Patients Aged 65 Years and Over With Intermediate-or High-Grade Non-Hodgkin's Lymphoma

    Chairperson: Eric Michael Bessell. Telephone: 115-969-11-69. Lead organization: Cancer Research Campaign Clinical Trials Unit-Birmingham (CRCTU). Age range: 65 and over.

  • NCCTG-N9921 Phase II Study of Carboplatin and Paclitaxel in Elderly Patients With Metastatic or Recurrent Unresectable Non-Small Cell Lung Cancer

    Chairperson: Aminah Jatoi. Telephone: 507-284-2511. Lead organization: North Central Cancer Treatment Group. Age range: 65 and over.

  • ITA-MILES, EU-98019, ITAGOCSI-MILES Phase III Randomized Study of Vinorelbine, Gemcitabine, or Both in Elderly Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Chairperson: Cesare Gridelli. Telephone: 39-81-590-32-69. Lead organization: Istituto Nazionale per lo Studio e la Cura dei Tumori. Age range: 70 and over.

  • MRC-LEUK-MYEL-VIII, EU-94031 Phase III Randomized Study of ABCM (DOX/BCNU/CTX/L-PAM) vs ABCM Followed by Oral CTX/PRED for Induction of First Plateau Phase in Elderly Patients With Multiple Myeloma

    Chairperson: Ian C. M. MacLennan. Telephone: 44-21-414-4069. Lead organization: Medical Research Council's Working Party on Leukemia in Adults and Children. Age range: under 75.

  • MSKCC-98037, NCI-G99-1542 Phase I Pilot Study of Ras Peptide Cancer Vaccine in Patients With Myelodysplastic Syndrome

    Chairperson: Stephen D. Nimer. Telephone: 212-639-7871. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: over 17.

  • MDA-ID-99060, NCI-T99-0043 Phase I Study of 6-Hydroxymethylacylfulvene in Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

    Chairperson: Francis J. Giles. Telephone: 713-792-7305. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: 18 and over.

  • JHOC-99072307, NCI-T99-0092 Phase I Study of Azacitidine in Combination With Phenylbutyrate in Patients With Recurrent, Refractory, or Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Chairperson: Carole Miller. Telephone: 410-955-8603. Lead organization: Johns Hopkins Oncology Center. Age range: 18 and over.

  • MDA-DM-99290, NCI-450 Phase I Study of BMS-214662 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia in Blast Phase

    Chairperson: Jorge Cortes. Telephone: 713-794-5783. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: 15 and over.

  • MDA-DM-98187, NCI-T98-0001 Phase I Study of Dolastatin 10 in Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Phase

    Chairperson: Jorge Cortes. Telephone: 713-794-5783. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: not specified.

  • CWRU-1998, NCI-G00-1732, CWRU-059812 Phase I Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed or Refractory Acute Leukemia or Advanced Myelodys-plastic Syndrome

    Chairperson: Brenda W. Cooper. Telephone: 216-844-3213. Lead organization: Ireland Cancer Center. Age range: 12 and over.

  • JHOC-J9966, NCI-G00-1816, JHOC-99110501 Phase I Study of Nonmyeloablative Cyclophosphamide Plus Haploidentical Allogeneic Bone Marrow Transplantation in Patients With Hematologic Malignancies

    Chairperson: Paul V. O'Donnell. Telephone: 410-614-0205. Lead organization: Johns Hopkins Oncology Center. Age range: 0.5 to 70.

  • MDA-DM-99245, NCI-94 Phase I Study of PS-341 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia in Blast Phase

    Chairperson: Jorge Cortes. Telephone: 713-794-5783. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: 18 and over.

  • MDA-DM-99169, NCI-T99-0101 Phase I Study of R115777 in Patients With Myelodysplastic Syndrome

    Chairperson: Razelle Kurzrock. Telephone: 713-794-1226. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: 18 and over.

  • MSKCC-99057, NCI-G99-1661 Phase I Study of Sodium Salicylate in Patients With Advanced Myelodysplastic Syndrome or Refractory or Relapsed Acute Myelogenous Leukemia

    Chairperson: Stephen D. Nimer. Telephone: 212-639-7871. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: over 18.

  • MSKCC-99126, NCI-G00-1815 Phase I Study of Yttrium Y 90 Humanized Monoclonal Antibody M195 and Etoposide Followed by Autologous Peripheral Blood Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

    Chairperson: Peter Maslak. Telephone: 212-639-5518. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

  • UW-26-245-B, NCI-V96-0848 Phase I Trial of Subcutaneous Out-patient Interleukin-2 for Patients With Myelodysplastic Syndrome

    Chairperson: John A. Thompson. Telephone: 206-598-2514. Lead organization: University of Washington Medical Center. Age range: 15 and over.

  • MDA-DM-97325, NCI-T98-0017 Phase I/II Randomized Study of PR1 Leukemia Peptide Vaccine and Montanide ISA-51 in Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

    Chairperson: Jeffrey J. Moll-drem. Telephone: 713-792-2933. Lead organization: University of Texas - MD Anderson Cancer Center. Age range: over 18.

  • MDA-ID-99341, NCI-673 Phase I/II Study of Daunorubicin Liposomal and SU5416 in Patients With Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB), RAEB in Transformation, or Chronic Myelomonocytic Leukemia Refractory to Induction Chemotherapy

    Chairperson: Francis J. Giles. Telephone: 713-792-7305. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: 18 and over.

  • SUMC-NCI-38, NCI-38 Phase I/II Study of R115777 in Patients With Myeloproliferative Disorders

    Chairperson: Peter L. Greenberg. Telephone: 650-725-8355. Lead organization: Stanford University Medical Center. Age range: 21 and over.

  • AUH-MCP-70612-01, NCIV98-1485, AUH-MCP-70612-02P Phase I/II Study of Topotecan, Fludarabine, Cytarabine, and Filgrastim (T-FLAG) Induction Therapy Followed by Maintenance Therapy of Either Peripheral Blood Stem Cells or Isotretinoin in Patients With Poor Prognosis Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Recurrent or Refractory Acute Lymphocytic Leukemia

    Chairperson: Emmanuel C. Besa. Telephone: 215-842-6980. Lead organization: Medical College of Pennsylvania Hospital. Age range: 19 to 90.

  • NU-91H1T, NCI-G00-1688 Phase II Pilot Study of Busulfan and Etoposide With Autologous Bone Marrow Transplantation and Filgrastim (G-CSF) in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Chairperson: Martin Stuart Tall-man. Telephone: 312-695-6180. Lead organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: Physiologic 65 and under.

  • WSU-D-696-87, NCI-V93-0345 Phase II Study of Allogeneic or Syngeneic Bone Marrow Transplantation Following Cytoreduction With BU/CTX for Low-Risk and BU/ARAC/CTX for High-Risk Acute Nonlymphocytic Leukemia, Myelodys-plastic Syndromes, and Secondary Acute Myeloid Leukemia

    Chairperson: Chatchada Karanes. Telephone: 313-745-9082. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: 60 and under.

  • CHNMC-IRB-98056, NCI-V99-1533, ALZA-CHNMC-IRB-98056 Phase II Study of Amifostine, Topotecan, and Cytarabine in Patients With Poor Risk Myelodys-plastic Syndrome

    Chairperson: Henry C. Fung. Telephone: 626-359-8111. Lead organization: ALZA Corporation. Age range: 16 and over.

  • FHCRC-1478.00, NCI-G00-1793 Phase II Study of Anti-Thymocyte Globulin and Tumor Necrosis Factor Receptor IgG Chimera in Patients With Myelodysplastic Syndrome

    Chairperson: H. Joachim Deeg. Telephone: 206-667-5985. Lead organization: Fred Hutchinson Cancer Research Center. Age range: Any age.

  • CCUM-9906, NCI-T99-0069 Phase II Study of Azacitidine Plus Amifostine in Patients With Myelodysplastic Syndromes

    Chairperson: Harry Paul Erba. Telephone: 734-647-8921. Lead organization: University of Michigan Comprehensive Cancer Center. Age range: over 18.

  • CWRU-1494, NCI-V97-1361 Phase II Study of Busulfan, Cyclophosphamide, and Allogeneic Bone Marrow Transplantation in Patients With Leukemia, Myelodys-plastic Syndromes, Multiple Myeloma, or Lymphoma

    Chairperson: Hillard M. Lazarus. Telephone: 216-844-3629. Lead organization: Ireland Cancer Center. Age range: 50 and under.

  • MSKCC-98017, NCI-G98-1444 Phase II Study of Decitabine for Myelodysplastic Syndromes

    Chairperson: Richard C. Frank. Telephone: 212-639-7900. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 15 and over.

  • NU-91H4T, NCI-G00-1686 Phase II Study of High Dose Busulfan and Cyclophosphamide Followed By Allogeneic Bone Marrow Transplantation in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Chairperson: Martin Stuart Tall-man. Telephone: 312-695-6180. Lead organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: 16 to physiologic 60.

  • FHCRC-1297.00, NCI-H99-0028 Phase II Study of Iodine I 131 Monoclonal Antibody BC8 Plus Cyclophosphamide and Total Body Irradiation Followed by HLA Matched Related or Unrelated Bone Marrow Transplantation in Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Chairperson: Dana Christine Matthews. Telephone: 206-667-2966. Lead organization: Fred Hutchinson Cancer Research Center. Age range: 2 to 55.

  • JHOC-98071505, NCI-G99-1544, JHOC-J9852 Phase II Study of Sargramostim (GM-CSF) Following T-cell Depleted Allogeneic Bone Marrow Transplantation in Patients With Myelodysplastic Syndrome

    Chairperson: Paul V. O'Donnell. Telephone: 410-614-0205. Lead organization: Johns Hopkins Oncology Center. Age range: 18 to 65.

  • MCV-CCHR-9504-2X, NCIG98-1388, DUMC-75951 Phase II/III Randomized Study of Conventional vs T cell Depleted Unrelated Donor Bone Marrow Transplantation for Leukemia, Myelodysplasia, and Lymphoblastic Lymphoma

    Chairperson: Lee Ann Jensen. Telephone: 301-435-0066. Lead organization: Massey Cancer Center. Age range: 55 and under.

  • CWRU-4496, NCI-G97-1350, AMC-1C-93 Phase II Study of Oral Combination Chemotherapy and Granulocyte Colony-Stimulating Factor in Elderly Patients With Intermediate and High Grade Non-Hodgkin's Lymphoma

    Chairperson: Scot C. Remick. Telephone: 216-844-3361. Lead organization: Ireland Cancer Center. Age range: 60 and over.

  • PLCO-1, NCI-P93-0050 A 16-Year Randomized Screening Study for Prostate, Lung, Colorectal, and Ovarian Cancer - PLCO Trial

    Chairperson: John K. Gohagan. Telephone: 301-496-8544. Lead organization: Early Detection Branch. Age range: 55 to 74.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....